1-[[(1aS,7bS)-2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromen-6-yl]sulfonyl]piperidine | 186181-13-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-[[(1aS,7bS)-2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromen-6-yl]sulfonyl]piperidine
• CAS: 186181-13-5
• 化学式: C₁₆H₂₁NO₄S
• 分子量: 323.413
• InChiKey: VSSJKTLBTGWDRM-GJZGRUSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  67.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[[(1aS,7bS)-2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromen-6-yl]sulfonyl]piperidine 在 ammonium hydroxide 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 24.0h， 生成 (3S,4R)-4-Amino-2,2-dimethyl-6-(piperidine-1-sulfonyl)-chroman-3-ol
  参考文献：
  名称：

  Cardioselective Antiischemic ATP-Sensitive Potassium Channel (K_ATP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines

  摘要：

  The effect on potency and selectivity of modifications at the C6 position of the cardioprotective K-ATP Opener BMS-180448 (2) is described. Structure-activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat, hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 mu M) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating K-ATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1), These results support the hypothesis that the cardioprotective and vasorelaxant properties of K-ATP openers follow distinct structure-activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac K-ATP as its cardioprotective effects are abolished by the K-ATP blocker glyburide.

  DOI：

  10.1021/jm990196h
• 作为产物：
  描述：

  2,2-dimethyl-2H-1-benzopyran-6-sulfonyl chloride 在 sodium hypochlorite 、 4-苯基吡啶-N-氧化物 、 Jacobsen's catalyst 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 20.0h， 生成 1-[[(1aS,7bS)-2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromen-6-yl]sulfonyl]piperidine
  参考文献：
  名称：

  Cardioselective Antiischemic ATP-Sensitive Potassium Channel (K_ATP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines

  摘要：

  The effect on potency and selectivity of modifications at the C6 position of the cardioprotective K-ATP Opener BMS-180448 (2) is described. Structure-activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat, hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 mu M) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating K-ATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1), These results support the hypothesis that the cardioprotective and vasorelaxant properties of K-ATP openers follow distinct structure-activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac K-ATP as its cardioprotective effects are abolished by the K-ATP blocker glyburide.

  DOI：

  10.1021/jm990196h

文献信息

• NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS
  申请人：Zhang Xuqing

  公开号：US20070049556A1

  公开（公告）日：2007-03-01

  The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

  本发明涉及新型苯并吡喃衍生物，含有它们的药物组合物以及它们在治疗与钾通道相关的疾病中的应用。
• Discovery and structure–activity relationships of a novel series of benzopyran-based KATP openers for urge urinary incontinence
  作者：Xuqing Zhang、Yuhong Qiu、Xiaojie Li、Sheela Bhattacharjee、Morgan Woods、Patricia Kraft、Scott G. Lundeen、Zhihua Sui

  DOI：10.1016/j.bmc.2008.11.055

  日期：2009.1

  A novel series of benzopyran derivatives were synthesized and evaluated as K(ATP) channel openers. Structure-activity relationships were investigated around 4-position of the benzopyran nucleus. Optimization of 4-substituent with some heterocyclic rings led to compound 13b bearing a benzo[d] isoxazol-3-one moiety as a potent and selective KATP channel opener in vitro. In two anesthetized rat models of myogenic bladder overactivity, compound 13b was found to inhibit spontaneous bladder contractions. (C) 2008 Elsevier Ltd. All rights reserved.
• Small Molecule Mitochondrial F₁F₀ ATPase Hydrolase Inhibitors as Cardioprotective Agents. Identification of 4-(<i>N</i>-Arylimidazole)-Substituted Benzopyran Derivatives as Selective Hydrolase Inhibitors
  作者：Karnail S. Atwal、Paulina Wang、W. Lynn Rogers、Paul Sleph、Hossain Monshizadegan、Francis N. Ferrara、Sarah Traeger、David W. Green、Gary J. Grover

  DOI：10.1021/jm030291x

  日期：2004.2.1

  In this paper we show that 4-aryl-CH2-imidazole-substituted benzopyran compounds with 3S,4R-stereochemistry are cardioprotective by inhibiting the F1F0 mitochondrial ATP hydrolase. Compounds (e.g., 13) with 3R,4S-stereochemistry act as mitochondrial K-ATP openers. This resulted from an inversion of stereochemistry for the F1F0 mitochondrial ATP hydrolase vs mitochondrial K-ATP. Structure-activity relationships for the inhibition of mitochondrial ATP hydrolase are also delineated. It is not clear how 13 (3R,4S) can selectively inhibit the hydrolytic activity of the F1F0 mitochondrial enzyme without interfering with the synthase activity.
• US7812183B2
  申请人：——

  公开号：US7812183B2

  公开（公告）日：2010-10-12
• US7838553B2
  申请人：——

  公开号：US7838553B2

  公开（公告）日：2010-11-23